1. Home
  2. SNGX vs BREA Comparison

SNGX vs BREA Comparison

Compare SNGX & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • BREA
  • Stock Information
  • Founded
  • SNGX 1987
  • BREA 2022
  • Country
  • SNGX United States
  • BREA Ireland
  • Employees
  • SNGX N/A
  • BREA N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • BREA Services-Misc. Amusement & Recreation
  • Sector
  • SNGX Health Care
  • BREA Consumer Discretionary
  • Exchange
  • SNGX Nasdaq
  • BREA Nasdaq
  • Market Cap
  • SNGX 7.4M
  • BREA 8.7M
  • IPO Year
  • SNGX 1987
  • BREA 2023
  • Fundamental
  • Price
  • SNGX $2.32
  • BREA $0.64
  • Analyst Decision
  • SNGX
  • BREA
  • Analyst Count
  • SNGX 0
  • BREA 0
  • Target Price
  • SNGX N/A
  • BREA N/A
  • AVG Volume (30 Days)
  • SNGX 621.8K
  • BREA 61.2K
  • Earning Date
  • SNGX 03-14-2025
  • BREA 01-03-2025
  • Dividend Yield
  • SNGX N/A
  • BREA N/A
  • EPS Growth
  • SNGX N/A
  • BREA N/A
  • EPS
  • SNGX N/A
  • BREA N/A
  • Revenue
  • SNGX $364,183.00
  • BREA $2,872,101.00
  • Revenue This Year
  • SNGX N/A
  • BREA N/A
  • Revenue Next Year
  • SNGX $76.64
  • BREA N/A
  • P/E Ratio
  • SNGX N/A
  • BREA N/A
  • Revenue Growth
  • SNGX N/A
  • BREA 2338.69
  • 52 Week Low
  • SNGX $1.83
  • BREA $0.50
  • 52 Week High
  • SNGX $14.88
  • BREA $3.00
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 36.12
  • BREA 40.04
  • Support Level
  • SNGX $2.23
  • BREA $0.62
  • Resistance Level
  • SNGX $2.39
  • BREA $0.69
  • Average True Range (ATR)
  • SNGX 0.17
  • BREA 0.05
  • MACD
  • SNGX 0.01
  • BREA -0.01
  • Stochastic Oscillator
  • SNGX 22.12
  • BREA 15.31

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About BREA Brera Holdings PLC

Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.

Share on Social Networks: